Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > BIONICHE LIFE SCIENCES INC - BNC:TSX
View:
Post by culater on Nov 22, 2010 2:30pm

BIONICHE LIFE SCIENCES INC - BNC:TSX

t.bnc,   Someone posted to catch the wave up on this some time back at $ 1.80.   Seems this stock is suffering from the same symptoms as ISA.  They received a milestone payment of 4 million dollars for a successful phase 111 trial recently and now selling 20 million new shares to increase cash.  On the notice of a new share issue it has dropped to 1.47 and appears to be going lower.    As I have mentioned before, the best play on small pharma stocks for us retail investors is to follow the chart, do some DD, buy on the drops and wait for pending news to sell.

culater
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities